Oncotype DX® Colon Recurrence Score
AGE54

54-Year-Old Female Patient

with Stage II: T3 (N0) Tumor

Patient Details

Adenocarcinoma
Stage II: T3 (N0)
Low (1)
Negative
15
MMR-P (MSS)
Absent
Not Provided
Absent
Not Provided

Other Information:

Referred to medical oncology but not treated.


Clinical Experience

Prognosis for Stage II MMR-P Colon Cancer Patients Following Surgery Alone

The clinical validation study included stage II colon cancer patients from the surgery-alone arm of the QUASAR study (N=711)1 and a pre-specified analysis of the Recurrence Score result, in the context of T-stage and MMR status.

The average 3 year risk of recurrence for patients who had a Recurrence Score result of 27 was:

Impact of Nodes Assessed: For patients with ≥ 12 nodes examined the 3-year recurrence risk was lower than that shown in the Figure. For T3 MMR-P patients the reduction in risk ranged from 2% for low to 6% for high Recurrence Score results. For T4 MMR-P patients the reduction in risk ranged from 4% to 10% respectively. For all MMR-P patients with < 12 nodes examined, the recurrence risk was 2-3% higher.

Prognosis for Stage II MMR-P Colon Cancer Patients Following Adjuvant Chemotherapy

The clinical validation study included patients from the NSABP C-07 trial which randomized patients to 5FU/LV versus 5FU/LV+oxaliplatin; 264 patients were stage II, including 247 (94%) with T3 tumors. Of 213 patients with available MMR status, 82% were MMR-P.2

The average 5 year risk of recurrence for patients who had a Recurrence Score result of 27 was:

Impact of Nodes Assessed: The recurrence risk for patients with ≥ 12 nodes examined was lower than the risk for those with < 12 nodes examined.


Stage II References

1. Gray et al. J Clin Oncol. 2011.
2. Yothers et al. J Clin Oncol. 2013.

Disclaimer: These case studies are brought to you for educational purposes only and should not be interpreted as an endorsement of Genomic Health or its services by the submitting physician, or any other product or therapy. The information is sometimes related to interpretive diagnostic opinions of the treating physicians, and is not intended to represent the “standard of care.” The case studies reflect real life cases of patients who have used Oncotype DX, however they are individual results and results do vary. The examples are not necessarily representative of all of those who will use our clinical tests. Genomic Health does not endorse any of the contributors featured on this site.

Submit a Case

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus sodales ultricies elementum.

Online Ordering
& Reports

Login to the Physician Portal to place an order and view patient results.

 

To sign up, please call or email Customer Service at:
+1 (866) ONCOTYPE (866-662-6897)
customerservice@genomichealth.com.

Contact

Contact your Regional Oncogenomic Liaison for more information or to submit a case study.

Recurrence Score®27